Department of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan Province, China.
Research Center of Digestive Diseases, Central South University, Changsha, 410011, Hunan Province, China.
Surg Endosc. 2024 Jul;38(7):3503-3519. doi: 10.1007/s00464-024-10862-3. Epub 2024 May 23.
Peroral endoscopic myotomy (POEM) is an emerging effective treatment for achalasia. However, a significant proportion of patients do not respond well to the treatment. After over a decade of clinical practice, potential risk factors associated with POEM failure have been identified. This meta-analysis aimed to summarize the evidence of risk factors for POEM failure.
A systematic literature search was conducted on PubMed, Embase, Web of Science, and Cochrane Library from inception to June 10th, 2022. We included English studies that reported POEM outcomes in achalasia patients and identified risk factors for POEM failure. Relevant information was extracted and analyzed using fixed- or randomized-effect models to pool the effect size.
A total of 27 studies comprising 9371 patients with achalasia were included in this review. The pooled failure rate was 8% (90% CI 7%-10%). We identified sigmoid esophagus (OR 1.90, 95% CI 1.45-2.47), type I achalasia (OR 1.30, 95% CI 1.04-1.63), and type III achalasia (OR 1.26, 95% CI 0.89-1.78) were associated with a worse clinical response. Conversely, type II achalasia was associated with a better response (OR 0.59, 95% CI 0.47-0.75). Prior treatment with Heller myotomy (OR 5.75, 95% CI 3.97-8.34) and prior balloon dilation (OR 1.18, 95% CI 1.07-1.29) were also associated with a higher risk of clinical failure.
Our meta-analysis results demonstrated that sigmoid esophagus, manometric achalasia subtype, and prior treatment were associated with POEM failure. This information could be used to guide treatment decisions and improve the success rate of POEM in achalasia patients.
经口内镜下肌切开术(POEM)是治疗贲门失弛缓症的一种新兴有效方法。然而,相当一部分患者对该治疗方法反应不佳。经过十多年的临床实践,已经确定了与 POEM 失败相关的潜在危险因素。本荟萃分析旨在总结 POEM 失败的危险因素的证据。
从建库到 2022 年 6 月 10 日,我们在 PubMed、Embase、Web of Science 和 Cochrane Library 上进行了系统的文献检索,纳入了报道贲门失弛缓症患者 POEM 结局并确定 POEM 失败危险因素的英文研究。提取相关信息,并使用固定或随机效应模型进行分析,以汇总效应量。
本综述共纳入了 27 项研究,共 9371 例贲门失弛缓症患者。总的失败率为 8%(90%CI 7%-10%)。我们发现,乙状结肠型食管(OR 1.90,95%CI 1.45-2.47)、Ⅰ型贲门失弛缓症(OR 1.30,95%CI 1.04-1.63)和Ⅲ型贲门失弛缓症(OR 1.26,95%CI 0.89-1.78)与较差的临床反应相关。相反,Ⅱ型贲门失弛缓症与更好的反应相关(OR 0.59,95%CI 0.47-0.75)。先前接受过 Heller 肌切开术(OR 5.75,95%CI 3.97-8.34)和先前接受过球囊扩张术(OR 1.18,95%CI 1.07-1.29)也与临床失败的风险增加相关。
本荟萃分析结果表明,乙状结肠型食管、测压贲门失弛缓症亚型和先前治疗与 POEM 失败相关。这些信息可以用于指导治疗决策,并提高 POEM 在贲门失弛缓症患者中的成功率。